A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This Phase Ib/IIa study has been designed according to a 3+3 dose escalation/dose expansion
design. A dose expansion will be conducted at both the intermediate and high dose levels, if
tolerated, with the purpose of generating additional and more robust safety and preliminary
efficacy data. No control arm was included, as the target patient population of this study
consists of patients in whom the overall survival is less than 6 months and treatment options
are very limited and often poorly tolerated, making unlikely that the study results can be
significantly biased.